Separation, Purification Or Synthesis Patents (Class 530/369)
  • Patent number: 10617123
    Abstract: Disclosed are compositions comprising chitosan, glucosamine and amino acids, where the concentration of chitosan is greater than 1.5 wt % and glucosamine is greater than 1.5 wt %. In preferred embodiments the concentration of chitosan is from 2 to 2.5 wt % and glucosamine is 2 to 6 wt %. The composition can also include solid chitin. The composition can also include trace elements, protein and other polysaccharides. The composition is generally a liquid but may be a solid. In most embodiments, the solid can be reconstituted with water prior to use. In preferred embodiments, the composition comprises HYTd and at least one of, HYTa, HYTb and HYTc. In other embodiments the composition comprises HYTd and two or more of, HYTa, HYTb and HYTc. The composition can also comprise HYTd, HYTa, HYTb and HYTc. In the disclosed processes soil, seed, seedling or plant foliage are contacted with HYTd or any of the above compositions.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: April 14, 2020
    Assignee: Agrinos AS
    Inventor: Jaime López-Cervantes
  • Publication number: 20150119554
    Abstract: A recombinant fusion protein comprising the moieties Band CT, and optionally REP, wherein B is comprising at least one immunoglobulin fragment, which provides the capacity of selective interaction with an organic target; CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein; and REP is a moiety of from 70 to 300 amino acid residues and is derived from the repetitive fragment of a spider silk protein.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 30, 2015
    Applicants: IMMUNOVIA AB, SPIBER TECHNOLOGIES AB
    Inventors: My Hedhammar, Jan Johansson, Anna Rising, Per Åke Nygren
  • Publication number: 20140206844
    Abstract: Described is a method for isolating multiple blood products from a single starting material. Isolation of multiple blood products from a single starting material maximizes the efficiency of blood product isolation. In the present invention, one or more blood products are isolated from a blood product material previously depleted of inter-alpha inhibitor protein (I?Ip). This method provides new paths for increasing the efficiency of isolating blood components and providing pharmaceutically acceptable forms of those components.
    Type: Application
    Filed: January 16, 2014
    Publication date: July 24, 2014
    Applicant: ProThera Biologics
    Inventor: Yow-Pin LIM
  • Publication number: 20140205839
    Abstract: The subject of the present invention is a pure monomeric bovine serum albumin, a method of producing it characterised by the use column chromatography in resin and a method of identifying it using dynamic light scattering.
    Type: Application
    Filed: May 6, 2012
    Publication date: July 24, 2014
    Applicant: WROCLAWSKIE CENTRUM BADAN EIT + SP Z O.O.
    Inventors: Jadwiga Pietkiewicz, Agnieszka Szydelko, Katarzyna Dzierzba, Regina Danielewicz, Magdalena Staniszewska, Arkadiusz Bartys, Andrzej Gamian
  • Publication number: 20140163101
    Abstract: Described herein are methods for inactivating viruses using caprylate in solutions containing albumin.
    Type: Application
    Filed: July 25, 2013
    Publication date: June 12, 2014
    Applicant: GRIFOLS, S.A.
    Inventors: Wytold Lebing, Doug Burns, Nathan Roth, Joann Hotta
  • Publication number: 20140093981
    Abstract: The method of the present disclosure is characterized by that one molecule of the amino acid is interposed between the self-assembled monolayer and the molecule of the albumin. For example, a method is provided for immobilizing albumin on a self-assembled monolayer, the method including the following steps (a) and (b) in this order: a step (a) of preparing a substrate including one molecule of an amino acid and the self-assembled monolayer and a step (b) of supplying the albumin to the substrate to form a peptide bond represented by a predetermined chemical formula as a result of reaction between the carboxyl group of the one molecule of the amino acid and the amino group of the albumin.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Applicant: PANASONIC CORPORATION
    Inventor: Yukari HATAOKA
  • Publication number: 20140031527
    Abstract: The present invention provides a method of polishing albumin to remove contaminants comprising passing an albumin enriched solution through a hydrophobic charge-induction chromatographic resin and recovering the albumin solution which passes through the resin. Also provided is a polished albumin solution prepared by said method.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 30, 2014
    Applicant: CSL LIMITED
    Inventors: Karl Beaumont McCANN, Joseph BERTOLINI
  • Publication number: 20140007547
    Abstract: A method for inactivation or removal of coagulation factors FII, FVII, FVIIa, FIX, FIXa, FX, FXI and FXIa in or from protein containing solutions obtained from blood, blood plasma, plasma fractions or by recombinant means wherein the protein containing solution is contacted with an organic acid or its salt while being stirred.
    Type: Application
    Filed: February 3, 2012
    Publication date: January 9, 2014
    Applicant: OCTAPHARMA AG
    Inventors: Waltraud Kaar, Alfred Zochling, Karin Ahrer
  • Publication number: 20130330276
    Abstract: A conjugate of human albumin (HA) and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (p-SCN-Bn-DOTA) insoluble in aqueous medium at a pH of 3-8.5 and whose IR spectrum shows an absorption at about 700 cm?1 is described; a complex is further described consisting of a conjugate of HA and p-SCN-Bn-DOTA (HAC) according to claim 1 or 2 and a radioactive isotope of an element selected among the group consisting of P, Sr, Rh, Pd, I, Sm, Er, Au, At Bi, In, Lu, Y, Re, Cu and Ag, as well as procedures for preparing said conjugate and said complex as well as the use of such conjugate in the identification of mammalian neoplastic lesions by the R.O.L.L. methodology (“Radioguided Occult Lesion Localization”).
    Type: Application
    Filed: December 23, 2011
    Publication date: December 12, 2013
    Applicants: ISTITUTO EUROPEO DI ONCOLOGIA S.R.L., UNIVERSITÀ DEGLI STUDI DI GENOVA
    Inventors: Gabriele Caviglioli, Brunella Parodi, Sergio Cafaggi, Eleonora Russo, Paola Cirrincione, Marco Chinol, Giovanni Paganelli
  • Publication number: 20130316376
    Abstract: A protein structure capable of selective interaction with an organic target is provided. The protein structure is a polymer comprising as a repeating structural unit a recombinant fusion protein that is capable of selective interaction with the organic target. The fusion protein is comprising the moieties B, REP and CT, and optionally NT. B is a non-spidroin moiety of more than 30 amino acid residues, which provides the capacity of selective interaction with the organic target. REP is a moiety of from 70 to 300 amino acid residues and is derived from the repetitive fragment of a spider silk protein. CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein. NT is an optional moiety of from 100 to 160 amino acid residues and is derived from the N-terminal fragment of a spider silk protein. The fusion protein and protein structure thereof is useful as an affinity medium and a cell scaffold material.
    Type: Application
    Filed: October 25, 2011
    Publication date: November 28, 2013
    Applicant: SPIBER TECHNOLOGIES AB
    Inventors: My Hedhammar, Jan Johansson, Anna Rising, Per Åke Nygren
  • Publication number: 20130280814
    Abstract: The present invention relates to a method for labeling proteins in a sample prior to separation thereof using a protein reactive dye, comprising the following steps a) dissolving the proteins in, or diluting the proteins with, or exchanging an existing protein buffer with, a labeling buffer comprising a dye-reactant (reacting with the protein reactive dye) to form a mixture, b) adding protein reactive dye to said mixture, c) incubating said mixture wherein the labeling of said proteins with said dye can be completed within 5 minutes, and wherein both the proteins and the dye-reactant form measurable reaction products with said dye, and d) separating said reaction products. The invention also relates to a kit for pre-labeling of proteins, comprising a labeling buffer, a dye, a molecular weight marker, and a sample gel loading buffer.
    Type: Application
    Filed: May 24, 2011
    Publication date: October 24, 2013
    Applicant: GE HEALTHCARE BIO-SCIENCES AB
    Inventor: Elsemarie Bjellqvist
  • Publication number: 20130231287
    Abstract: The present invention provides an albumin polymer and a process of making an albumin polymer, the process comprising breaking instrinsic disulfide bridges in albumin with a reducing agent and crosslinking inter- and intra-molecular disulfide bridges so as to form the polymer. The present invention also provides PEGylated albumin polymers and methods of making PEGylated albumin polymers, the methods comprising polymerizing albumin by crosslinking inter- and intra-molecular disulfide bridges, and PEGylating the albumin polymer. The present invention further provides a pharmaceutical composition useful as a blood plasma expander, blood substitute or for drug delivery, and methods of treating blood loss in a subject and of delivering drugs to a subject's tissue, the pharmaceutical composition comprising a therapeutically effective amount of the PEGylated albumin polymer.
    Type: Application
    Filed: February 22, 2011
    Publication date: September 5, 2013
    Inventors: Parimala Nacharaju, Marcos Intaglietta
  • Patent number: 8513383
    Abstract: Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: August 20, 2013
    Assignee: Heliae Development, LLC
    Inventor: Aniket Kale
  • Patent number: 8513384
    Abstract: Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: August 20, 2013
    Assignee: Heliae Development, LLC
    Inventor: Aniket Kale
  • Publication number: 20130164827
    Abstract: The present invention provides methods for separating proteins from a protein mixture. In one aspect, a method for separating a high concentration protein mixture into a bound protein fraction and a flow-through protein fraction can include delivering a protein mixture through an ion exchange column at a fixed pH and a fixed salt concentration. The fixed pH and the fixed salt concentration have been preselected to cause separation of the protein mixture into a bound protein fraction and a flow-through protein fraction. In this case, the bound protein fraction binds to the ion exchange column and the flow-though protein fraction flows though the ion exchange column. The method can further include receiving the flow-through protein fraction from the ion exchange column separate from the bound protein fraction, wherein either the bound protein fraction or the flow-through fraction contains a protein of interest.
    Type: Application
    Filed: November 5, 2012
    Publication date: June 27, 2013
    Inventor: Anthony R. Torres
  • Patent number: 8303922
    Abstract: A new method is disclosed for the exfoliation of hexagonal boron nitride into mono- and few-layered nanosheets (or nanoplatelets, nanomesh, nanoribbons). The method does not necessarily require high temperature or vacuum, but uses commercially available h-BN powders (or those derived from these materials, bulk crystals) and only requires wet chemical processing. The method is facile, cost efficient, and scalable. The resultant exfoliated h-BN is dispersible in an organic solvent or water thus amenable for solution processing for unique microelectronic or composite applications.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: November 6, 2012
    Assignee: The United States of America as represeted by the Administrator of the National Aeronautics and Space Administration
    Inventors: Yi Lin, John W. Connell
  • Patent number: 8258264
    Abstract: An albumin preparation may be produced efficiently on a commercial basis that has reduced possibility of contamination of infectious viruses and has high safety and stability. The process according to the present invention comprises a step of filtration of a serum albumin-containing solution with a virus-removing membrane preferably with a pore size of 10 to 20 nm. In particular, said filtration is performed before heat treatment for inactivation of viruses. In a more preferable embodiment, said serum albumin-containing solution is treated with an anion exchanger and/or a prefilter before a step of said filtration.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: September 4, 2012
    Assignee: Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Rikiichi Tagawa, Yoshihiro Hayase, Kota Maemura, Hisashi Tanigawa
  • Publication number: 20120202973
    Abstract: A method for extracting recombinant human serum albumin (rHSA) from transgenic rice grain is provided, comprising the steps of: 1) grinding dehusked rice containing rHSA into milled rice grain with a fineness of 80˜120 mesh, which is mixed with a extraction buffer in a w/v ratio of 1:5, then extracting at 55˜60° C. for 1˜3 hours to obtain mixture I; said extraction buffer comprises 10˜30 mM phosphate buffer, 10˜20 mM sodium acetate, 15˜30 mM ammonium sulfate and 5˜20 mM sodium caprylate and has a pH of 6.5˜8; 2) adjusting the pH of mixture I to 4.0˜4.5, followed by precipitating at room temperature for 3˜12 hours to obtain mixture II; 3) filtering the mixture II and collecting the filtrate, to obtain a solution containing high concentration of rHSA. The concentration of rHSA in the resultant solution is 650˜660 ?g/mL, which increases by 1.15 times comparing to the extraction amount before improvement, and the amount of non-target protein is reduced by 2.46 times.
    Type: Application
    Filed: August 10, 2011
    Publication date: August 9, 2012
    Applicant: Healthgen Biotechnology Co., Ltd.
    Inventors: Daichang Yang, Yang He, Guangfei Li
  • Publication number: 20120149873
    Abstract: An improved method for purifying albumin, a variant or fragment thereof, a fusion protein comprising albumin, a variant or fragment thereof, or a conjugate comprising albumin, a variant or fragment thereof is disclosed.
    Type: Application
    Filed: May 7, 2010
    Publication date: June 14, 2012
    Applicant: NOVOZYMES BIOPHARMA DK A/S
    Inventors: Lee Edward Blackwell, Jason Cameron, Phillip Harvey Morton
  • Publication number: 20120053323
    Abstract: Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.
    Type: Application
    Filed: November 4, 2011
    Publication date: March 1, 2012
    Inventor: Aniket Kale
  • Publication number: 20120022234
    Abstract: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.
    Type: Application
    Filed: September 17, 2010
    Publication date: January 26, 2012
    Inventors: Nathalie Bousquet-Gagnon, Omar Quraishi, Dominique P. Bridon
  • Publication number: 20110313132
    Abstract: The present invention provides processes for the production of preformed albumin conjugates. In particular, the invention provides processes for the in-vitro conjugation of a therapeutic compound to recombinant albumin, wherein a therapeutic compound comprising a reactive group is contacted to recombinant albumin in solution to form a conjugate. The processes provide for conjugation to albumin species of increasing homogeneity. The resulting conjugate is purified by chromatography, in particular hydrophobic interaction chromatography comprising phenyl sepharose and butyl sepharose chromatography.
    Type: Application
    Filed: March 14, 2011
    Publication date: December 22, 2011
    Inventors: Dominique P. BRIDON, Nathalie BOUSQUET-GAGNON, Omar QURAISHI
  • Publication number: 20110312027
    Abstract: Provided are methods of making carrier polypeptide that include incorporating a first unnatural amino acid into a carrier polypeptide variant, incorporating a second unnatural amino acid into a target polypeptide variant, and reacting the first and second unnatural amino acids to produce the conjugate. Conjugates produced using the provided methods are also provided. In addition, orthogonal translation systems in methylotrophic yeast and methods of using these systems to produce carrier and target polypeptide variants comprising unnatural amino acids are provided.
    Type: Application
    Filed: December 9, 2009
    Publication date: December 22, 2011
    Inventors: Travis Young, Peter G. Schultz
  • Publication number: 20110301329
    Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilised aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.
    Type: Application
    Filed: July 1, 2011
    Publication date: December 8, 2011
    Applicant: Novozymes Biopharma DK A/S
    Inventors: Hendrik Van Urk, David John Mead, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michel Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Darrell Sleep, Jean-Luc Bernard Veron
  • Publication number: 20110293594
    Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
    Type: Application
    Filed: May 26, 2011
    Publication date: December 1, 2011
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Wolfgang Teschner, Hans-Peter Schwarz, Ruth Madlener, Sonja Svatos, Azra Pljevljakovic, Alfred Weber
  • Publication number: 20110245466
    Abstract: The invention concerns the method of production of a polyanionic macromolecule which is a protein built, among others, form polar amino acids (such as lysine, arginine, aspartic acid, glutamic acid), characteristic in that, that as a result of the reaction between amine groups and the cyclic anhydride of dicarboxylic acid, the charge changes towards more negatively charged carrier. This reaction gives rise to better therapeutic properties of macromolecules modified in this way.
    Type: Application
    Filed: October 23, 2009
    Publication date: October 6, 2011
    Inventors: Janusz Boratynski, Mohamed Salah Omar Megahed, Urszula Kanska, Dmitry Nevozhay, Joanna Wietrzyk
  • Publication number: 20110152503
    Abstract: The instant invention provides novel and effective methods of isolating alpha-1-antitrypsin from cryo-poor plasma and formulating it into therapeutic products. This invention achieves higher yields and a superior quality of alpha-1-antitrypsin. Alpha-1-antitrypsin is isolated from cryo-poor plasma, using one or more salts selected from a group comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride in two fractionation steps, followed by diafiltration to remove those salts employed.
    Type: Application
    Filed: December 20, 2010
    Publication date: June 23, 2011
    Inventors: Gene Zurlo, Dennis Curtin, Allan Louderback
  • Publication number: 20110046054
    Abstract: The present invention relates to a novel hypoglycemic/anti-hyperglycemic protein named ADMc1 purified from the seeds of Momordica charantia for control of hyperglycemia. The process for the purification of novel hypoglycemic/anti-hyperglycemic protein named ADMc1 is also disclosed. The invention also relates to process for preparation and purification of the recombinant novel hypoglycemic/anti-hyperglycemic protein of Momordica charantia, named rADMc1. Both ADMc1 and rADMc1 are highly effective and need to be administered only once a day to maintain normal blood glucose levels. The procedure involves purification of a novel hypoglycemic/anti-hyperglycemic protein of M. charantia, construction of cDNA library from M. charantia seeds, screening of cDNA library using oligonucleotide probe designed on the basis of amino acid sequence of the tryptic fragment of the protein, cloning of the cDNA in a eukaryotic expression system, expression and purification of the recombinant protein.
    Type: Application
    Filed: March 28, 2008
    Publication date: February 24, 2011
    Inventors: Aparna Dixit, Aruna Vashishta, Tejram Sahu, Shailesh Kumar Choudhary, Alli Murugesan
  • Publication number: 20110045223
    Abstract: A new method is disclosed for the exfoliation of hexagonal boron nitride into mono- and few-layered nanosheets (or nanoplatelets, nanomesh, nanoribbons). The method does not necessarily require high temperature or vacuum, but uses commercially available h-BN powders (or those derived from these materials, bulk crystals) and only requires wet chemical processing. The method is facile, cost efficient, and scalable. The resultant exfoliated h-BN is dispersible in an organic solvent or water thus amenable for solution processing for unique microelectronic or composite applications.
    Type: Application
    Filed: August 24, 2009
    Publication date: February 24, 2011
    Applicant: United States of America as represented by the Administrator of the National Aeronautics and Spac
    Inventors: Yi Lin, John W. Connell
  • Publication number: 20100210821
    Abstract: A process for isolation and purification of a target protein by chromatography wherein the chromatography removes or depletes prions (PrPSC), comprising the steps of contacting a potentially PrPSC contaminated sample comprising a target protein with a multimodal chromatographic material; setting buffer conditions so that the target protein is bound to the multimodal chromatographic material and whereas PrPSC is not binding to the multimodal chromatographic material; followed by elution of the target protein. a process for isolation and purification of a target protein free of prion protein (prpSC).
    Type: Application
    Filed: August 25, 2008
    Publication date: August 19, 2010
    Inventors: Gustav Gilljam, Mats Jernberg, Stefan Winge, Andrea Neisser-Svae
  • Publication number: 20100167374
    Abstract: The present invention relates to a chromatographic method of separating biological material comprising, providing chromatographic media comprising inorganic oxide particles having an average diameter of about 2 microns or less and an average pore diameter of 300 ? or more; applying a solvent comprising said biological material to said media, wherein said biological material is reversibly bonded to said media; and eluting said biological material from said media with a solvent in less than about 2 minutes for biological material having a molecular weight of less than about 100,000 Daltons.
    Type: Application
    Filed: February 21, 2008
    Publication date: July 1, 2010
    Inventors: Reno T. Nguyen, Scott Anderson, Ian Chappell
  • Patent number: 7700732
    Abstract: An albumin containing fraction having a reduced prekallikrein activator (PKA) content and a method of manufacturing same comprising the steps of: (a) reconstitution of paste V (Cohn fractionation), (b) performing a concentration step of the fraction obtained in step (a), (c) heating the fraction obtained in step (b) in a range of from 50° C. to 70° C. for a sufficient time to pasteurize the fraction, and (d) optionally filling of the obtained fraction for use.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: April 20, 2010
    Assignee: Octapharma AG
    Inventors: Werner Gehringer, Katharina Pock
  • Patent number: 7695973
    Abstract: The present invention provides methods for quantitation of glycated protein in a biological sample using a solid support matrix by making a first bound protein measurement total bound protein under conditions where both glycated and non-glycated protein bind to the support in making a second bound protein measurement under conditions where glycated protein is bound to the support and non-glycated protein is not substantially bound. Diagnostic devices and kits comprising the methods of the present invention are also provided.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: April 13, 2010
    Assignee: Scripps Laboratories, Inc.
    Inventors: Ralph P. McCroskey, Cameron E. Melton
  • Publication number: 20100029546
    Abstract: Preparation of galactose albumin adriamycin magnetic nanoparticles: in order to prepare galactose albumin magnetic nanoparticle, cottonseed oil and magnetic nano powder is needed. Mix galactose albumin, adriamycin and magnetic nanoparticle at a proportion, and get the particle through emulsification in cottonseed oil, heating for solidification, and diethyl ether washing. This invention couples galactose to the surface of nanoparticle to form galactose nanoparticle, which targets actively and passively to improve the drug targeting level to liver. Modifying albumin adriamycin magnetic nanoparticles with galactose enhances its targeting level.
    Type: Application
    Filed: September 24, 2004
    Publication date: February 4, 2010
    Inventor: Yangde Zhang
  • Publication number: 20100004178
    Abstract: A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.
    Type: Application
    Filed: September 10, 2009
    Publication date: January 7, 2010
    Inventors: Ragheb Assaly, John D. Dignam, Joseph I. Shapiro
  • Publication number: 20090099337
    Abstract: The present invention provides an S-nitroso group-containing albumin, comprising an S-nitroso group introduced to at least one lysine in the amino acid sequence for albumin. The S-nitro group has been introduced into a lysine in the S-nitroso group-containing albumin of the invention to allow more S-nitroso groups to be included in the albumin, thus ensuring more potent inhibition of cancer cells in NO groups.
    Type: Application
    Filed: August 29, 2008
    Publication date: April 16, 2009
    Applicant: NIPRO CORPORATION
    Inventors: Masaki Otagiri, Keisuke Nakajo, Naohisa Katayama, Toshiya Kai
  • Patent number: 7195923
    Abstract: The present invention provides methods for determining a ratio of an amount of a glycated form of a protein to a total amount of the protein in a sample containing the glycated protein, the glycosylated protein, or the glycoprotein. The method incorporates lateral flow test strip or vertical flow test strip devices having negatively charged carboxyl or carboxylate groups and hydroxyboryl groups immobilized and interspersed on a solid support matrix. The solid support matrix may include derivatives of cellulose (e.g., carboxy cellulose) derivatized with carboxylic acid (e.g., carboxylate, carboxyl) groups and hydroxyboryl compounds including phenylboronic acid (e.g., phenylborate), aminophenylboronic acid, boric acid (e.g., borate), or other boronic acid (e.g., boronate) compounds. The present invention is usefi.il for monitoring glycation or glycosylation of hemoglobin or albumin for monitoring glycemic control (e.g., glycemia in diabetes).
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: March 27, 2007
    Assignee: Scripps Laboratories, Inc.
    Inventors: Ralph P. McCroskey, Cameron E. Melton
  • Patent number: 6469145
    Abstract: Novel and improved processes for isolating organophosphorus hydrolase enzyme from an aqueous solution and obtaining substantially purified enzyme at high yield are provided, as well as compositions, including storage stable lyophilyzed organophosphorus hydrolase enzyme compositions, that are prepared by the provided methods. The organophosphorus hydrolase enzyme is purified by contacting an aqueous solution of cell free bacterial proteins with a strong cation exchange resin, the aqueous solution comprising soluble organophosphorus hydrolase enzyme, washing the strong cation exchange resin with a washing buffer to remove unbound proteins from the strong cation exchange resin, eluting proteins that remain bound to the strong cation exchange resin by washing the resin with an eluting buffer comprising salt in a concentration that starts at about zero and is raised during the eluting process to about 0.5M, and detecting and collecting eluate comprising a protein having organophosphorus hydrolase enzyme activity.
    Type: Grant
    Filed: June 26, 2000
    Date of Patent: October 22, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Vipin K. Rastogi, Tu-Chen Cheng, Joseph J. DeFrank
  • Publication number: 20020132986
    Abstract: A method is provided for removing citrate, aluminum, and other multivalent ions and contaminants from proteins by adjusting the pH of a solution containing the protein to a pH from about 7 to about 10, and diafiltering the pH-adjusted solution against aqueous solutions which have a low level of ions.
    Type: Application
    Filed: December 26, 2000
    Publication date: September 19, 2002
    Inventors: Raja R. Mamidi, Leticia R. Regis, Mauro C. Mojica, Hirokazu Ito, Takashi Goto
  • Patent number: 6429297
    Abstract: The present invention relates to a compound of the formula These modified streptavidin compounds have are useful as part of a delivery system to deliver a molecule to a target site for use in diagnosis or therapy.
    Type: Grant
    Filed: February 3, 2000
    Date of Patent: August 6, 2002
    Assignee: University of Rochester
    Inventor: Scott F. Rosebrough
  • Patent number: 6022722
    Abstract: The invention relates to a method for the renaturation of denatured proteins in which they are treated with a renaturant which has on vicinal carbon atoms a hydroxyl group and at least one fluorine atom.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: February 8, 2000
    Assignee: Huels Aktiengesellschaft
    Inventors: Frauke Lohr, Andreas Pawlik, Hubert Motschmann, Martina Bree, Euridice Vieira, Alexander Welle
  • Patent number: 5770378
    Abstract: Tricyclic retinoids having activity for retinoic acid receptors and/or retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such tricyclic retinoid compounds and methods for their therapeutic use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 23, 1998
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Chan Kou Hwang, Steven K. White, Youssef L. Bennani, Stacie S. Canan Koch, Beth Ann Badea, Jonathan J. Hebert, Alex M. Nadzan
  • Patent number: 5770382
    Abstract: Tricyclic retinoids having activity for retinoic acid receptors and/or retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such tricyclic retinoid compounds and methods for their therapeutic use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 23, 1998
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Chan Kou Hwang, Steven K. White, Beth Ann Badea, Alex M. Nadzan
  • Patent number: 5770383
    Abstract: Tricyclic retinoids having activity for retinoic acid receptors and/or retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such tricyclic retinoid compounds and methods for their therapeutic use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 23, 1998
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Chan Kou Hwang, Steven K. White, Youssef L. Bennani, Stacie S. Canan Koch, Beth Ann Badea, Jonathan J. Hebert, Luc J. Farmer, Alex M. Nadzan
  • Patent number: 5322930
    Abstract: An improved method for expressing peptides as fusion proteins, uses a carrier for a heterologous peptide to provide a fusion protein having a high pI. The high isoelectric point facilitates separation of the fusion protein from all other host cell proteins, and separation of the carrier from the peptide after cleavage.
    Type: Grant
    Filed: November 12, 1992
    Date of Patent: June 21, 1994
    Assignee: Scios Nova Inc.
    Inventors: S. Joseph Tarnowski, Sandra Hilliker, W. Scott Willett
  • Patent number: 5310878
    Abstract: A biosynthetic cerebrospinal fluid control and method of use. Additionally, this invention relates to the isolation and purification of stable liquid human prealbumin, a component in the biosynthetic cerebrospinal fluid control.
    Type: Grant
    Filed: October 23, 1992
    Date of Patent: May 10, 1994
    Assignee: Baxter Diagnostics Inc.
    Inventor: Kathryn D. Herring
  • Patent number: 5277818
    Abstract: An albumin preparation having a polymer content of not more than 3% by weight based on the serum albumin content and an .alpha..sub.1 -AGP content of not more than a detectable limit based on the serum albumin content, which is prepared by removing a polymer-forming factor from an albumin aqueous solution by, for example, ion exchange separation or affinity chromatography, and subjecting the solution to a heat treatment.
    Type: Grant
    Filed: April 22, 1993
    Date of Patent: January 11, 1994
    Assignee: The Green Cross Corporation
    Inventors: Yasushi Matsuoka, Shinichiro Hase, Kazuo Takechi, Shinji Tomioka, Kazumasa Yokoyama
  • Patent number: 5136021
    Abstract: A TNF-inhibitory protein having a molecular weight of 28 kilodaltons and having an activity of rendering resistant to TNF a TNF- sensitive cell to thereby inhibit the cytolytic and/or cytostatic activity of TNF for the TNF-sensitive cells and a method for producing the same are described. The TNF-inhibitory protein can advantageously be used as an antigen for producing an antibody useful for detecting a patient having TNF-resistant cancer and for removing the TNF-resistance of the cancer cells of the patient.
    Type: Grant
    Filed: February 27, 1990
    Date of Patent: August 4, 1992
    Assignee: Health Research, Inc.
    Inventors: Wlodzimierez E. Dembinski, Margot Ip
  • Patent number: 5071650
    Abstract: Soluble, intermediate length alcohols (C.sub.4 -C.sub.10) in aqueous solutions at low pH (4.0-7.0) can be used as virucidal agents for therapeutic biologically active protein preparations. Treatment with the alcohols is especially useful for proteins having activity not adversely affected by low pH.
    Type: Grant
    Filed: June 4, 1990
    Date of Patent: December 10, 1991
    Assignee: Miles Inc.
    Inventors: George B. Dove, Milton B. Dobkin, Michael A. Shearer
  • Patent number: 4841023
    Abstract: There is disclosed a process for rendering a labile protein-containing composition, substantially free of lipid-containing viruses without incurring substantial protein denaturation comprising contacting said composition with an effective amount of a fatty acid or a soluble ester, alcohol or a salt thereof for a sufficient period of time to inactivate virus contained therein.
    Type: Grant
    Filed: June 25, 1986
    Date of Patent: June 20, 1989
    Assignee: New York Blood Center, Inc.
    Inventor: Bernard Horowitz